Aim: The Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus (T2DM), and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide.
Methods: Based on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide (n = 400) and Xiaoke Pill (n = 400), after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups (with/without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group). We screened the differential serum proteins related to treatments and the onset of hypoglycemia using the iTRAQ labeling quantitative proteomics technique. Baseline and follow-up samples were used.
Results: The quantitative proteomics experiments demonstrated that 25 and 21 proteins differed upon treatment with the Xiaoke Pill in patients without and with hypoglycemia, respectively, while 24 and 25 proteins differed upon treatment with Glibenclamide in patients without and with hypoglycemia, respectively. The overlap of different proteins between the patients with and without hypoglycemia given the same drug treatment was much greater than between the patients given different drug treatments.
Conclusions: We conclude that the serum proteins response to the two different anti-diabetic drug treatments may serve as a sensitive biomarker for evaluation of the therapeutic effects and continue investigations into the mechanism.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436452 | PMC |
| http://dx.doi.org/10.1186/s12014-017-9154-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-Effectiveness of Oral Antidiabetic Drugs: A Prospective Multicenter Study of Real-World Patients.
Evid Based Complement Alternat Med
October 2021
Visible Analytics, Oxford OX20DP, UK.
This real-world, multicenter, prospective study aims to analyze the cost-effectiveness of prevalent oral antidiabetic drugs, including traditional Chinese medicine and its compounds, used in China. Type 2 diabetes patients initiated on one or several of the most prevalent antidiabetic drugs were recruited on the baseline and followed up over one year with no restriction on drug discontinuation, switching, and add-on. Different drugs were evaluated on their efficacy, adverse effect (AE), health-related quality of life (HRQoL), and cost.
View Article and Find Full Text PDFAnalysis of the Health Information Needs of Diabetics in China.
Stud Health Technol Inform
August 2019
Department of General Practice, Zhongshan Hospital affiliated to Shanghai Fudan University, Shanghai, China.
According to the latest statistics of the China National Health Protection Commission, the prevalence of adult diabetics in China has reached 11.6%, and the number of patients has exceeded 114 million. Understanding the needs of diabetics and what kind of problems they are anxious about are crucial for doctors, hospitals and other health care providers, which can be used to ameliorate patient education services and help patients to improve their disease management skills.
View Article and Find Full Text PDFEffect of astragaloside IV on diabetic gastric mucosa and .
Am J Transl Res
November 2017
Laboratory Animal Center, Guangzhou University of Chinese MedicineGuangzhou, China.
This study evaluated the effects of AS-IV on high glucose induced-gastric mucosal lesions compared to the effects of the Bu-zhong-yi-qi pill and the Xiaoke pill, which are already in clinical use. STZ-induced diabetic SD rats were treated with drugs for 12 weeks. Diabetes serum (DS) was used to mimic high glucose conditions in GES-1 cells at different concentrations and time points.
View Article and Find Full Text PDFThe serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients.
Clin Proteomics
May 2017
CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101 China.
Aim: The Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus (T2DM), and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide.
Methods: Based on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide (n = 400) and Xiaoke Pill (n = 400), after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups (with/without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group).
Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.
J Diabetes
December 2017
Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Center, Beijing, China.
Background: The aim of the present study was to investigate the value of clinical characteristics in predicting sulfonylurea (SU) treatment responses.
Methods: All 747 subjects in the present study were from the Xiaoke Pill Clinical Trial evaluating the safety and efficacy of SU. Subjects had the same initial dose of glibenclamide and drug doses were adjusted every 4 weeks during the 48-week follow-up period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!